Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes

Diabetes Care

Volumn 36, Issue 11, 2013, Pages 3510-3516

  Neugebauer, Romain ^a   Fireman, Bruce ^a   Roy, Jason A ^b   O'Connor, Patrick J ^c  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Health Partners Institute for Education and Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ALBUMINURIA; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LEG AMPUTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PATIENT COMPLIANCE; PATIENT SAFETY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RETINA MACULA EDEMA; REVASCULARIZATION; RISK ASSESSMENT; YOUNG ADULT; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MIDDLE AGED; MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

ADULT; AGED; ALBUMINURIA; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 84891875247     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2675     Document Type: Article

References (24)

1. American Diabetes Association. Standards of medical care in diabetesd2012. Diabetes Care 2012;35(Suppl. 1):S11-S63
2. Institute for Clinical Systems Improvement. Diagnosis and management of type 2 diabetes mellitus in adults [article online], 2012. Available from https://www .icsi.org/guidelines-more/catalog-guidelines-and-more/catalog- guidelines/catalog-endocrine-guidelines/diabetes/. Accessed 14 May 2012
3. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
4. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
5. DuckworthW, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360: 129-139
6. Ismail-Beigi F, Craven T, Banerji MA, et al.; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-430
7. O'Connor PJ, Ismail-Beigi F. Nearnormalization of glucose and microvascular diabetes complications: data from ACCORD and ADVANCE. Ther Adv Endocrinol Metab 2011;2:17-26
8. Gerstein HC, Miller ME, Genuth S, et al.; ACCORD Study Group. Long-termeffects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364:818-828
9. Tunstall-Pedoe H. Validity of ICD code 410 to identify hospital admission for myocardial infarction. Int J Epidemiol 1997;26:461-462
10. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004;148:99-104
11. Friedman GD, Klatsky AL, Siegelaub AB, McCarthy N. Kaiser-Permanente epidemiologic study of myocardial infarction. Study design and results for standard risk factors. Am J Epidemiol 1974;99:101-116
12. RosamondWD, Chambless LE, Sorlie PD, et al. Trends in the sensitivity, positive predictive value, false-positive rate, and comparability ratio of hospital discharge diagnosis codes for acute myocardial infarction in four US communities, 1987-2000. Am J Epidemiol 2004;160:1137-1146
13. HammarN,Nerbrand C, Ahlmark G, et al. Identification of cases of myocardial infarction: hospital discharge data and mortality data compared to myocardial infarction community registers. Int J Epidemiol 1991;20:114-120
14. Neugebauer R, Fireman B, Roy JA, O'Connor PJ, Selby JV. Dynamic marginal structural modeling to evaluate the comparative effectiveness of more or less aggressive treatment intensification strategies in adults with type 2 diabetes. Pharmacoepidemiol Drug Saf 2012;21 (Suppl. 2):99-113
15. Robins J. Marginal structural models. In 1997 Proceedings of the American Statistical Association, Section on Bayesian Statistical Science, 1998. American Statistical Association 16. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-570
16. Cook NR, Cole SR, Hennekens CH. Use of amarginal structuralmodel to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. Am J Epidemiol 2002;155:1045-1053
17. Bodnar LM, Davidian M, Siega-Riz AM, Tsiatis AA. Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology. Am J Epidemiol 2004;159: 926-934
18. van der Laan MJ, Petersen ML. Causal effect models for realistic individualized treatment and intention to treat rules. Int J Biostat 2007;3:Article 3
19. Robins J, Orellana L, Rotnitzky A. Estimation and extrapolation of optimal treatment and testing strategies. Stat Med 2008; 27:4678-4721
20. Robins J. Association, causation and marginal structural models. Synthese 1999; 121:151-179
21. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168:656-664
22. Moore KL, Neugebauer R, van der Laan MJ, Tager IB. Causal inference in epidemiological studies with strong confounding. Stat Med 2012;31:1380-1404
23. UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998;317:720-726
24. Hernan MA. The hazards of hazard ratios. Epidemiology 2010;21:13-15